Search Results - Markus Perl

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases by Leonard Knoedler, Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Konstantin Herfeld, Helia Hosseini, Sam Boroumand, Viola A. Stoegner, Viola A. Stoegner, Ali-Farid Safi, Ali-Farid Safi, Markus Perl, Markus Perl, Samuel Knoedler, Samuel Knoedler, Bohdan Pomahac, Martin Kauke-Navarro

    Published in Frontiers in Immunology (2024-04-01)
    Get full text
    Article


  2. 2

    Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy by Stefan Enssle, Anna Sax, Peter May, Nadia El Khawanky, Nardine Soliman, Markus Perl, Julius C. Enssle, Karsten Krey, Jürgen Ruland, Andreas Pichlmair, Florian Bassermann, Hendrik Poeck, Simon Heidegger

    Published in OncoImmunology (2025-12-01)
    Get full text
    Article


  3. 3

    Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies by Markus Perl, Konstantin Herfeld, Dennis C. Harrer, Matthias Höpting, Marina Schweiger, Ulrich Sterz, Leonard Knödler, Susanne Heimerl, Leo Hansmann, Wolfgang Herr, Hendrik Poeck, Daniel Wolff, Matthias Edinger, Christina Hart, Matthias A. Fante

    Published in Haematologica (2024-03-01)
    Get full text
    Article


Search Tools: